Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) FCF Margin (2016 - 2025)

IGC Pharma (IGC) has disclosed FCF Margin for 16 consecutive years, with 1109.42% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin fell 86064.0% to 1109.42% in Q3 2025 year-over-year; TTM through Sep 2025 was 508.68%, a 8510.0% decrease, with the full-year FY2025 number at 386.07%, up 1073.0% from a year prior.
  • FCF Margin was 1109.42% for Q3 2025 at IGC Pharma, down from 431.4% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 183.39% in Q1 2024 to a low of 4167.86% in Q3 2021.
  • A 5-year average of 1092.77% and a median of 671.69% in 2022 define the central range for FCF Margin.
  • Biggest YoY gain for FCF Margin was 613201bps in 2021; the steepest drop was -197026bps in 2021.
  • IGC Pharma's FCF Margin stood at 1724.65% in 2021, then soared by 61bps to 671.69% in 2022, then fell by -21bps to 811.27% in 2023, then surged by 36bps to 522.96% in 2024, then tumbled by -112bps to 1109.42% in 2025.
  • Per Business Quant, the three most recent readings for IGC's FCF Margin are 1109.42% (Q3 2025), 431.4% (Q2 2025), and 226.67% (Q1 2025).